Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Prana Biotechnology Investor Presentation

June 27, 2018August 16, 2022 Alterity Therapeutics

1_Prana Biotechnology Investor Presentation_2018-0627 final

2018

Post navigation

Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases

First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases

Related Posts

Abstract from Movement Disorders Conference

June 22, 2016August 16, 2022

Prana Announces that New York Academy of Sciences eBriefing available online

July 17, 2013August 16, 2022

Prana Announces Successful Phase 2 Results in Huntington Disease Trial

February 18, 2014August 16, 2022

Recent Posts

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
Alterity Therapeutics to Present at MST Financial Webinar
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
Webcast Presentation on New Data from the bioMUSE Natural History Study

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065